Latest Hotspot

LegChem Bio has entered into a licensing deal for their Trop2-focused antibody-drug conjugate known as LCB84

2 January 2024
3 min read

LegoChem Biosciences, Inc., revealed on the 22nd of December its new licensing partnership with Janssen Biotech, Inc., part of the Johnson & Johnson family of companies, for the advancement and marketing of their specialized therapeutic, LCB84, an antibody-drug conjugate targeting Trop2.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Pursuant to the contractual arrangement, LCB confers upon Janssen a sole and universal entitlement to proceed with the research, development, and marketing of LCB84. LCB stands to receive as much as USD 1.7 billion consisting of several financial components, namely a preliminary disbursement of USD 100 million, a payment of USD 200 million upon exercising the option, in addition to potential payments tied to developmental, regulatory, and sales milestones, paired with escalating royalties predicated on global sales.

A Joint effort will persist throughout the ongoing early-stage clinical research; thereafter, upon exercising the option, Janssen will become the exclusive party in charge of the clinical advancement and market introduction of the product. The ADC, LCB84, harnesses the novel Trop2 axis and embodies LCB's cutting-edge ADC technological framework, along with a Trop2 antibody, under a licensing agreement from Mediterranea Theranostic, S.r.l. It is currently under investigation in an early-phase clinical trial in the United States.

Showcasing a novel targeted approach, the ADC binds a distinct cleavable variant of the Trop2 antigen, which shows elevated expression within tumor cells. Preclinical studies reveal that LCB84 stands out due to its safety and efficacy profile when evaluated over a diverse array of cancer types, enhancing its potential as a therapeutic ADC aimed at Trop2.

LCB's chief executive, Yong-Zu Kim, stated, "We are delighted to be in collaboration with Janssen regarding LCB84, marking our inaugural internally generated ADC in clinical development." He further expressed eagerness in fortifying LCB's international clinical development and fostering additional ADC initiatives towards clinical trials.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面

中度可信度描述已自动生成

According to the data provided by the Synapse Database, As of December 30, 2023, there are 1 investigational drugs for the Trop-2 and Tubulin target, including 7 indications, 1 R&D institutions involved, with related clinical trials reaching 19, and as many as 198 patents.

LCB-84 targets Trop-2 and Tubulin proteins and shows potential in treating various neoplastic diseases, digestive system disorders, endocrinology and metabolic diseases, hemic and lymphatic diseases, skin and musculoskeletal diseases, and respiratory diseases. The drug is currently in Phase 1/2 of development, indicating its progress in clinical trials. Further research is needed to determine its safety, efficacy, and potential impact on patient outcomes.

图形用户界面, 文本

描述已自动生成

Understanding 5-HT1A receptor agonists and Methods to Keep Abreast of Their Recent Developments
Understanding 5-HT1A receptor agonists and Methods to Keep Abreast of Their Recent Developments
2 January 2024
5-HT1A receptor agonists are drugs that activate the 5-HT1A receptor, used in treating conditions like anxiety, depression, and schizophrenia.
Read →
Zealand Pharma submits FDA approval request for glepaglutide to treat short bowel syndrome
Latest Hotspot
3 min read
Zealand Pharma submits FDA approval request for glepaglutide to treat short bowel syndrome
2 January 2024
Zealand Pharma has officially presented a request for drug approval to the United States' FDA for their medication glepaglutide, aiming to treat individuals with short bowel syndrome.
Read →
What is the difference between Fast Track Designation and Breakthrough therapy Designation?
"What" Series
2 min read
What is the difference between Fast Track Designation and Breakthrough therapy Designation?
2 January 2024
The U.S. FDA offers Fast Track Designation and Breakthrough Therapy Designation to speed up the development and review of drugs for serious conditions lacking treatments. Yet, they differ in key aspects.
Read →
Senti Bio granted FDA approval for SENTI-202, targeting resistant blood cancers like Acute Myeloid Leukemia
Latest Hotspot
3 min read
Senti Bio granted FDA approval for SENTI-202, targeting resistant blood cancers like Acute Myeloid Leukemia
2 January 2024
Senti Bio has received the green light from the FDA for SENTI-202, aimed at addressing recurring or stubborn blood cancers, such as Acute Myeloid Leukemia.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.